Therapeutic Strategies in Congenital Myasthenic Syndromes

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 542-547

  Schara, Ulrike ^a   Lochmüller, Hanns ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

3; 4 diaminopyridine (3; 4 DAP); acetazolamide; acetylcholinesterase inhibitor; Congenital myasthenic syndrome; ephedrine; fluoxetine; quinidine sulfate; therapy

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETAZOLAMIDE; EPHEDRINE; FLUOXETINE; QUINIDINE SULFATE;

ARTICLE; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; ELECTROPHYSIOLOGY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPONATREMIA; INSOMNIA; MEDICAL ASSESSMENT; METABOLIC DISORDER; NAUSEA; NERVOUSNESS; NEUROMUSCULAR JUNCTION DISORDER; PRIORITY JOURNAL; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; MYASTHENIC SYNDROMES, CONGENITAL; NOOTROPIC AGENTS;

EID: 53049097589     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.07.003     Document Type: Article

References (30)

1. Beeson D., Hantaï D., Lochmüller H., and Engel A.G. 126th International Workshop: Congenital Myasthenic Syndromes, 24-26 September 2004, Naarden, The Netherlands. Neuromuscul Disord 15 (2005) 498-512
2. Engel A.G., Ohno K., and Sine S.M. Congenital myasthenic syndromes. In: Engel A.G., and Franzini-Armstrong C. (Eds). Myology. 3rd ed. (2004), McGraw-Hill, New York 1801-1844
3. Engel A.G., and Sine S.M. Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 5 (2005) 308-321
4. Engel A.G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4 (2007) 252-257
5. Croxen R., Hatton C., Shelley C., et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 59 (2002) 162-168
6. Ohno K., Tsujino A., Brengman J.M., et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 98 (2001) 2017-2022
7. Ohno K., Brengman J.M., Tsujino A., and Engel A.G. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A 95 (1998) 9654-9659
8. Donger C., Krejci E., Serradell A.P., et al. Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am J Hum Genet 63 (1998) 967-975
9. Middleton L., Ohno K., Christodoulou K., et al. Chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor ε-subunit gene. Neurology 53 (1999) 1076-1082
10. Engel A.G., Ohno K., Milone M., et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5 (1996) 1217-1227
11. Ohno K., Engel A.G., Shen X.M., et al. Rapsyn mutations in humans cause endplate acetylcholine receptor deficiency and myasthenic syndrome. Am J Hum Genet 70 (2002) 875-885
12. Chevessier F., Faraut B., Ravel-Chapuis A., et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 13 (2004) 3229-3240
13. Beeson D., Higuchi O., Palace J., et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 3 (2006) 1975-1978
14. Tsujino A., Maertens C., Ohno K., et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci U S A 100 (2003) 7377-7382
15. Hantaï D., Richard P., Koenig J., and Eymard B. Congenital myasthenic syndromes. Curr Opin Neurol 17 (2004) 539-551
16. Gurnett C.A., Bodnar J.A., Neil J., and Connolly A.M. Congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy. J Child Neurol 19 (2004) 175-182
17. Bestue-Cardiel M., Sáenz de Cabezón-Alvarez A., Capablo-Liesa J.L., et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65 (2005) 144-146
18. Schara U., Deschauer M., Wendt M., et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 17 (2007) 818-819 (abstract)
19. Schara U., Christen H.J., Hietala M., et al. Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. Neuromuscul Disord 17 (2007) 818 (abstract)
20. Harper C.M., Fukodome T., and Engel A.G. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60 (2003) 1710-1713
21. Colomer J., Müller J.S., Vernet A., et al. Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 16 (2006) 329-333
22. Palace J., Wiles C.M., and Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54 (1991) 1069-1072
23. Sieb J., and Engel A.G. Ephedrine: effects on neuromuscular transmission. Brain Res 623 (1993) 167-171
24. Mihaylova V., Müller J.S., Vilchez J.J., et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 131 (2008) 747-759
25. Miller J.B., and Girgenrath M. The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol Med 12 (2006) 279-286
26. Vohra B.P.S., Groshong J.S., Zayas R., Wollmann R.L., and Gomez C.M. Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis 23 (2006) 462-470
27. 2+ overload in slow-channel syndrome. Cell Calcium 41 (2007) 343-352
28. Müller J.S., Baumeister S.K., Rasic V.M., et al. Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations. Neurology 67 (2006) 1159-1164
29. Müller J.S., Baumeister S.K., Schara U., et al. CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn. Brain 129 (2006) 2784-2793
30. Slater C.R., Fawcett P.R.W., Walls T.J., et al. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia.'. Brain 129 (2006) 2061-2076